Luke Roberts, MBBS, PhD, on Developing Gene Therapy for Congestive Heart Failure

Commentary
Video
Conferences|American Society for Gene & Cell Therapy (ASGCT)

The medical director of clinical development at AskBio discussed the progress of an early clinical trial of AB-1002.

“One in 4 adults is likely to have heart failure at some point in their life. So, there's really an urgent need to develop new therapies and treatments. Because although there are a number of even fairly recently approved medicines for heart failure, the residual risk of heart failure patients is extremely high. For those patients with more advanced symptoms for whom those treatments may no longer be as effective, there are very few additional therapeutic options for those patients.”

Data from a phase 1 trial (NCT05598333) of AB-1002 gene therapy in patients with congestive heart failure look promising, with a manageable safety profile and some improvements in disease measures including New York Heart Association (NYHA) class III functional score, Left Ventricular Ejection Fraction, and quality of life measures.

Data from the trial were presented at the American Society of Gene & Cell Therapy (ASGCT) 27th Annual Meeting, held May 7 to 10, 2024, in Baltimore, Maryland, by Luke Roberts, MBBS, PhD, Medical Director, Clinical Development, Asklepios BioPharmaceutical.

CGTLive® spoke with Roberts to learn more about the unmet need for patients with congestive heart failure, especially for those with more advanced symptoms of the disease. He discussed AB-1002 and the chimeric vector that differentiates it from other gene therapies and how it may help improve outcomes in patients with congestive heart failure. He gave an overview of the phase 1/2 trial assessing AB-1002 and its progress.

Click here to read more coverage of the 2024 ASGCT Annual Meeting.

REFERENCE
Roberts L, Henry T, Chung E, et al. Safety and Efficacy of AB-1002 Gene Therapy in Patients with Advanced Heart Failure: Results from an Ongoing Phase 1 Clinical Trial. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract #9
Recent Videos
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
David Porter, MD, the director of cell therapy and transplant at Penn Medicine
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Ben Samelson-Jones, MD, PhD, assistant professor pediatric hematology, Perelman School of Medicine, University of Pennsylvania and Associate Director, Clinical In Vivo Gene Therapy, Children’s Hospital of Philadelphia
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program in the Division of Hematology/Oncology at David Geffen School of Medicine at University of California, Los Angeles (UCLA)

Evaluating Lyell’s CAR-T IMPT-314 in LBCL

Sarah Larson, MD;Noah Stansfield
January 28th 2025
Article

Sarah Larson, MD, the medical director of the Immune Effector Cell Therapy Program at UCLA, discussed initial data from a phase 1/2 trial.

ImmunoLogic

CGTLive® Presents: ImmunoLogic, A Video Podcast With Joseph Fraietta, PhD

Joseph A. Fraietta, PhD;Noah Stansfield;Matt Hoffman
December 18th 2024
Podcast

Hosted by Joseph Fraietta, PhD, ImmunoLogic will be tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility.

John Leonard, MD, the president and chief executive officer of Intellia

First Patient Dosed in Phase 3 Trial for Intellia Therapeutics’ Hereditary Angioedema Gene Editing Therapy NTLA-2002

Noah Stansfield
January 23rd 2025
Article

The company stated it expects to submit a BLA to the FDA next year.

Jonathan Parker, MD, PhD, an assistant professor of neurosurgery at Mayo Clinic Arizona

The Promise of Cell Therapy Approaches in Epilepsy

Marco Meglio
December 17th 2024
Podcast

Mind Moments®, a podcast from our sister site NeurologyLive®, held an exclusive interview with Jonathan Parker, MD, PhD.

Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Garners Fast Track Designation

Solid Biosciences’ Friedreich Ataxia Gene Therapy SGT-212 Garners Fast Track Designation

Noah Stansfield
January 21st 2025
Article

SGT-212, a dual route gene transfer therapy, is intended to be delivered both by intradentate nucleus infusion and IV infusion at the same time.

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado

Transplant Eligibility Versus CAR-T Eligibility

Manali Kamdar, MD;Noah Stansfield
January 16th 2025
Article

Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado, discussed the importance of referring patients with r/r LBCL who are transplant ineligible for CAR-T treatment.

© 2025 MJH Life Sciences

All rights reserved.